Korean J Med.  2014 Jan;86(1):1-13. 10.3904/kjm.2014.86.1.1.

HLA Mismatch Allogeneic Blood and Marrow Transplantation

• Kim HJ

• KMID: 1867309
• DOI: http://doi.org/10.3904/kjm.2014.86.1.1

Abstract

A full haplotype mismatch or mismatched unrelated donor transplantation nowadays are well being focused on, as main alternative donor tools for acute leukemia patients in desperate need of allogeneic blood and marrow transplantation (BMT), the ability to overcome various posttransplant complications by adopting the T-cell replete technique in reality. Increasing numbers of allogeneic BMT in good clinical status are largely because it's the best post-remission therapy especially for many patients with acute leukemias. Due to the problems of unavailable donors at appropriate clinical condition and the process of long duration of donor searching step with relatively much higher cost, some of physicians have indulged in haploidentical BMT rather than mismatched unrelated BMT. Both myeloablative and reduced intensity conditioning regimens for mismatched BMT with T-cell replete or T-cell depletion method have been exploited worldwide. Most of all, Asian countries have experienced lower rates of severe acute and chronic GvHD, graft failure, and impressively low transplant-related mortality with longer follow-up duration. Also, we need many future trials to compare outcomes between these two transplant modalities with cord blood transplant in various diseased patient populations.

Keyword

Haplotype mismatch; Unrelated donor; BMT; T-cell replete or depletion; GvHD

MeSH Terms

Asian Continental Ancestry Group
Bone Marrow*
Fetal Blood
Follow-Up Studies
Haplotypes
Humans
Leukemia
Mortality
T-Lymphocytes
Tissue Donors
Transplants
Unrelated Donors